115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
    Meeting Abstract

    Oaknin, A.; Ang, J. E.; Rha, S. Y.; Yonemori, K.; Kristeleit, R.; Lin, C. C.; Satoh, T.; Garcia, P. E.; Sendur, M. A. N.; Rodríguez, L. M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
    Meeting Abstract

    Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Meeting Abstract

    Twelves, C. J.; Banerji, U.; Tap, W. D.; Cook, N.; Evans, T. R. J.; Plummer, R.; Anthoney, A.; Plummer, C.; Dawson, R.; Loadman, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
    Meeting Abstract

    Powles, T. B.; Bhatia, A. K.; Burtness, B.; Kogawa, T.; Nishina, T.; Nakayama, I.; Fountzilas, C.; Castillo, D. R.; McKean, M.; Meric-Bernstam, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
    Meeting Abstract

    Drilon, A. E.; Xu, R. H.; van Tilburg, C. M.; Doz, F.; Tan, D. S. W.; Lin, J. J.; Geoerger, B.; Zwaan, C. M.; Lassen, U. N.; Italiano, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
    Meeting Abstract

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R. S.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
    Meeting Abstract

    Guo, R.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save